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Activation of NF-kB has been noted in many tumor types, however only rarely has this been linked to
an underlying geneticmutation. An integrated analysis of high-density oligonucleotide array CGHand
gene expression profiling data from 155multiple myeloma samples identified a promiscuous array of
abnormalities contributing to the dysregulation of NF-kB in approximately 20%of patients.We report
mutations in ten genes causing the inactivation of TRAF2, TRAF3, CYLD, cIAP1/cIAP2 and activation
of NFKB1, NFKB2, CD40, LTBR, TACI, and NIK that result primarily in constitutive activation of the
noncanonical NF-kB pathway, with the single most common abnormality being inactivation of
TRAF3. These results highlight the critical importance of the NF-kB pathway in the pathogenesis
of multiple myeloma.INTRODUCTION
Multiple myeloma (MM) is a late stage B cell malignancy
characterized by the accumulation of a monoclonal
plasma cell population in the bone marrow. One-half of
all patients have recurrent immunoglobulin gene translo-
cations mediated by aberrant class switch recombination
events, while the other half are hyperdiploid (Bergsagel
et al., 1996; Fonseca et al., 2003b). However, both groups
are characterized by dysregulation of a cyclin D gene,
which appears to be an early and unifying event in MM
pathogenesis (Bergsagel et al., 2005). A variety of second-
ary genetic events, associated with disease progression
have been observed and include deletion of chromosome13, amplification of chromosome 1q, deletion of TP53, ac-
tivating pointmutations of ras, and translocations of c-myc
(Kuehl and Bergsagel, 2002). In addition to these known
genetic events, the activation of NF-kB, by mechanisms
that remain unclear, is thought to be a common event in
MM. The activation of the NF-kB pathway by mutation
has only been described in a singleMMpatient with an ac-
tivating mutation of NFKB2 (Fracchiolla et al., 1993). Nev-
ertheless, the importance of this pathway in MM is high-
lighted by the clinical success of proteasome inhibitors
(Richardson et al., 2003), which have been postulated to
act principally by inhibiting NF-kB (Rajkumar et al., 2005).
The transcriptional regulation of NF-kB target genes
is mediated by an array of homo- and heterodimersSIGNIFICANCE
Activation of the canonical NF-kB pathway has been recognized in patients with multiple myeloma and attributed
to interactions of themyeloma cell with the bonemarrowmicroenvironment. We report a promiscuous array ofmu-
tations that result in constitutive activation of primarily the noncanonical NF-kB pathway in one-fifth of patients.
The genetic selection of thesemutations by the tumor cells highlights the critical importance of the NF-kBpathway
in myeloma and suggests an important mechanism by which the tumor cells can begin to become independent of
the microenvironment. Our results suggest that proteasome inhibitors that target the NF-kB pathwaymay bemost
effective in those patients with mutations causing constitutive activation of NF-kB.Cancer Cell 12, 131–144, August 2007 ª2007 Elsevier Inc. 131
Cancer Cell
Mutations in the Noncanonical NF-kB Pathway in MMcontaining p50 and p52, the active isoforms of
NFKB1(p105) and NFKB2(p100) respectively (Hoffmann
and Baltimore, 2006). The function of these dimers is de-
pendent on ubiquitin mediated proteasomal degradation;
however, the regulation of this process is different for di-
mers containing p50 or p52. The classical or ‘‘canonical’’
NF-kB pathway is negatively regulated by the inhibitors
of NF-kB (IkBs), which retain p50-containing complexes
in the cytoplasm to prevent their function as transcription
factors. Therefore, the canonical pathway is not regulated
by the processing of NFKB1 as the inactivation of the IkB
complex is the rate-limiting step in the activation of the
canonical pathway. In contrast, the ‘‘noncanonical’’ NF-kB
pathway is solely regulated by the control of NFKB2(p100)
processing to the active p52 isoform (Dejardin, 2006). The
control of this process is dependent upon the presence of
NF-kB-inducing kinase (MAP3K14/NIK), a protein that is
normally undetectable as it is cotranslationally degraded
in a TNF-receptor-associated factor 3 (TRAF3)-dependent
manner (Liao et al., 2004). Consistently, Traf3/mice are
characterized by constitutive processing of NFKB2 (He
et al., 2006). Another TNF-receptor-associated factor,
TRAF2, may also play a role in the control of NIK function
as a conditional Traf2 knock-out in B cells results in con-
stitutive processing of NFKB2 (Grech et al., 2004).
The importance of the noncanonical NF-kB pathway in
B cell development has been established in a number of
model systems (Sen, 2006). First, the classical alympho-
plasia mouse phenotype is caused by a missense muta-
tion of Nik (Nikaly/aly) that prevents the induction of
NFKB2 processing (Shinkura et al., 1999). Additionally,
Nfkb2/ mice display a reduced B cell compartment,
poor germinal center development, but a normal T cell
compartment (Caamano et al., 1998; Franzoso et al.,
1998). Conversely, transgenic mice expressing constitu-
tively active isoforms of NFKB2, analogous to the ones
identified in a variety of lymphoid malignancies (Neri
et al., 1991), have an expansion of their B cell population
(Ciana et al., 1997; Ishikawa et al., 1997).
In addition to their role in B cell homeostasis, the NF-kB
pathways have been implicated in a wide variety of tu-
mors; however, only a limited number of activating muta-
tions have been reported (Courtois and Gilmore, 2006;
Karin, 2006). Using a combined strategy of high-resolution
array-based comparative genomic hybridization (aCGH)
and gene expression profiling (GEP), we have identified
abnormalities in a number of genes predicted to result in
dysregulation of primarily the noncanonical NF-kB path-
way. These mutations provide a genetic basis for the dys-
regulation of NF-kB in some cases of MM, and their
genetic selection highlights the paramount importance
of the NF-kB pathway in this disease.
RESULTS
aCGH Identifies Frequent Biallelic Deletions
of NF-kB Regulatory Genes
In order to identify genetic abnormalities in MM we
screened 62 patient samples and 46 human myeloma132 Cancer Cell 12, 131–144, August 2007 ª2007 Elsevier Inc.cell lines (HMCLs) originating from 42 individuals on
a high density oligonucleotide aCGH platform with
42,896 features at an average genomic interval of 35 kb
(Barrett et al., 2004). We took a reductionist approach to
the analysis of the aCGH data by focusing our analysis
on biallelic/homozygous deletion events, which are intrin-
sically limited to small genomic regions but are likely to
harbor tumor suppressor genes (see Figure S1 in the Sup-
plemental Data available with this article online). To ensure
that the observed biallelic deletions represented genuine
events and not noise in the data or large common nucleo-
tide variations (CNV) (Khaja et al., 2006; Redon et al.,
2006), we first applied a circular binary segmentation algo-
rithm (CBS) to the data (Olshen et al., 2004). The CBS
algorithm provides a very stringent means of identifying
biallelic deletions as it segregates chromosomal locations
into regions with significant adjacent mean copy number
changes. Although this reduced the resolution of the anal-
ysis from35kb to70kb, it significantly limits the number
of false positive events. This analysis scheme identified
13 biallelic deletion events in 11 patients, encompassing
43 genes, and 80 biallelic deletions in 36 HMCLs, encom-
passing 148 genes, that do not represent physiological re-
arrangements of immunoglobulin loci or aberrations within
previously characterized CNV regions (Table S1).
The only recurrent biallelic deletion identified by aCGH
in our patient samples occurred at 14q32 and encom-
passed three potential target genes; TRAF3, AMN, and
CDC42BPB (Figure 1 and Figure S2). Furthermore, this
abnormality was one of only two identified in both our
patient and HMCL data sets. We confirmed the biallelic
deletions by cIg-FISH, and the minimally deleted region
(MDR) was mapped by PCR in the two HMCLs with bial-
lelic deletions to a genomic region of <48.8 kb using se-
quence tagged site (STS) and fine mapping primer pairs
(Figure 1). This fine mapping approach eliminated
CDC42BPB as a target gene of the deletion and thus
only TRAF3 or AMN remained as potential target genes.
The remaining biallelic deletion identified in both of our
data sets occurred at 11q22. This deletion was often quite
large, ranging from 0.14–4.22 Mb in size; however, the
MDR defined by aCGH was <109.05 kb in size and en-
compassed only 2 genes; BIRC2/cIAP1 and BIRC3/
cIAP2 (Figure 1). As expected, the presence of a biallelic
deletion correlated with reduced expression of the pre-
dicted target gene (Figure S3).
Interestingly, inactivation of TRAF3, cIAP1/2, and CYLD
appears to be a common event in MM, as we identified
a number of potential biallelic deletions in the publicly
available data set from Carrasco et al. based on a corre-
lation between the aCGH copy number and the expres-
sion level (Figure S4) (Carrasco et al., 2006). Combining
these two patient data sets did not help to further refine
the MDR encompassing TRAF3 or cIAP1/2; however, it
did refine the MDR of the biallelic deletion we observed
at 16q12 to a 72.05 kb region, which includes two genes,
CARD15 and CYLD (Figure S4).
Interestingly, 5/13 (38.5%) of the biallelic deletion
events identified within our patient cohort contained
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Mutations in the Noncanonical NF-kB Pathway in MMFigure 1. High Resolution aCGH Identifies Biallelic Deletions of NFKB Regulatory Genes
(A) The biallelic deletions (TRAF3, cIAP1 or cIAP2, CYLD, and TRAF2) predicted to target NF-kB regulatory genes identified in our 62 MM patient and
46 HMCL aCGH cohorts are shown. All of the maps except the TRAF3map, which is drawn to relative scale so that the exon structure can be shown,
are drawn to scale. Black arrows above each gene represent the direction of transcription. For TRAF3, the direction of transcription follows the nu-
merical exon order and light gray exon regions indicate coding region. Each biallelic deletion is shown below the respective genomic map. Solid gray
bars indicate regions of biallelic deletion, solid gray lines indicated regions of biallelic deletion mapped by PCR, and dashed gray lines indicate the
region containing the breakpoint. The position and the copy number prediction of the aCGH probes contain on the microarray are indicated by red
(one or more copies) or green (zero copies) dots. The position of probes used for cIg-FISH are shown below each genomic map. Dashed vertical red
lines indicate the MDR identified by aCGH or PCR mapping.
(B) Representative images from the cIg-FISH validation of the aCGH findings are shown. Myeloma cells are identified by the blue cytoplasmic stain,
which indicates the presence of either cytoplasmic kappa or lambda light chains. In the cIAP1/2 and TRAF2 panels, a macrophage (kidney-shaped
nucleus) is shown that takes up the stain unspecifically. In the TRAF2 panel one of the three plasma cells shown still retains a copy of TRAF2, fitting the
observed frequency of biallelic TRAF2 deletions observed in this patient sample.potential target genes (TRAF2, TRAF3, cIAP1/2, and
CYLD) associated with the regulation of the NF-kB signal-
ing pathways. Based on these observations, we devel-
oped the working hypothesis that the frequent dysregula-
tion of NF-kB signaling observed in MM is often the result
of genetic abnormalities within the tumor cells.Combined Analysis of GEP and aCGH Data Sets
Identifies Additional Abnormalitieswithin Regulators
of the NF-kB Signaling Pathways
Our primary analysis of the aCGHdata sets identified inac-
tivation of 5 different genes involved in the NF-kB signaling
pathways. To build on these observations, we combinedCancer Cell 12, 131–144, August 2007 ª2007 Elsevier Inc. 133
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Mutations in the Noncanonical NF-kB Pathway in MMFigure 2. NFKB Related Genes with Spiked Expression Correlate with Genetic Abnormalities
(A) Representative plots indicating the regional copy number abnormality and corresponding gene expression level are shown. The gene of interest
is highlighted in red on each plot. The predicted number of gene copies is indicated on the top of each panel and the median normalized expres-
sion level is shown at the bottom. Each aCGH probe is represented by a dot and the color of each dot corresponds to the log2 ratio of the probe;
black dots, normal copy number (log2 ratio 0.25–0.25); green dots (log2 ratio < 0.25); red dots (log2 ratio > 0.25). The light gray region repre-
sents the mean copy number change identified by the CBS algorithm. Crosses indicate the gene expression probes for each gene and the log10
transformed expression levels are color coded to match the aCGH data. Pink circles highlight the expression probes corresponding to the gene of
interest.
(B) Representative cIg-FISH images are shown that document the rearrangements of NIK and LTBR in MM patients, the duplication and insertion of
CD40 into the Ig lambda locus, and the HSR containing TACI and NFKB1.134 Cancer Cell 12, 131–144, August 2007 ª2007 Elsevier Inc.
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identify additional abnormalities within genes involved in
the NF-kB signaling pathways. A screen of our 125 patient
and 44 HMCL GEP cohorts for spiked expression of
genes involved in the regulation of NF-kB signaling identi-
fied overexpression of MAP3K14/NIK, LTBR, CD40,
TNFRSF13B/TACI, and NFKB1 (Figure 2 and Figure S3).
We identified the dysregulated expression of NIK in two
HMCLs, L363 and EJM, that have previously been re-
ported to overexpress NIK by either a t(17;22) transloca-
tion or amplification, respectively (C. Annunziata et al.,
2006, Proc. Am. Assoc. Cancer Res., abstract). Because
of these observations, we examined the aCGH data sets
for abnormalities of the NIK locus. We confirmed the am-
plification in EJM and identified unbalanced rearrange-
ments of NIK in one HMCL, JJN-3, and one patient, which
were confirmed by cIg-FISH (Figure 2 and Figure S5).
We noted spiked expression of LTBR and CD40 in both
patient and HMCL cohorts. A >40-fold increase in the ex-
pression of LTBR was observed in one patient and in the
HMCL FR4. For FR4, aCGH showed a significant amplifi-
cation of the entire 12p chromosome arm, which was con-
firmed by FISH (Figure 2 and Figure S6). Interestingly,
LTBR is one of only six genes on the entire arm with
a >40-fold increase in expression. For the one patient
with spiked LTBR expression, aCGH data was not avail-
able; however, FISH identified a single copy gain of the
LTBR locus that is inserted at an unknown location
(Figure S6). Within the surrounding region, only LTBR
and VAMP1 are overexpressed in this patient
(Figure S6). For CD40, we identified one HMCL and two
patient samples with spiked expression. By aCGH, the
HMCL XG-2 contains a discrete two-copy gain of the
CD40 locus, which was confirmed by FISH and shown
to be associated with the Ig-lambda locus (Figure S7). In
the two patients with spiked CD40 expression, aCGH
data were not available and cIg-FISH did not detect
a copy number variability or rearrangement of CD40.
We also detected the spiked expression of
TNFRSF13B/TACI in the HMCL KMS-26 and NFKB1 in
OCI-MY5 and KMM-1. In both KMS-26 and OCI-MY5
the overexpression of TACI and NFKB1 were mirrored
by the presence of homologous staining regions contain-
ing the respective genes (Figure 2). In KMM-1, which had
a 19-fold increase in the expression of NFKB1, a detect-
able alteration by aCGH was not identified. However, by
FISH, an expression cloud was associated with a single
NFKB1 allele that disappeared following RNase treatment
(Figure S8), suggesting that an unknown mechanism is
driving the overexpression of NFKB1 from a single allele
in this HMCL.
Finally, we were able to correlate the presence of these
diverse mutations with increased NF-kB transcriptional
activity (Figure 2). The level of NF-kB-mediated transcrip-Ctional activity was determined based on a gene expres-
sion index developed from the HMCLs. We used an
ANOVA test using the error estimate from a crossgene
error model with multiple testing correction to identify six
probe sets (p < 0.05) differentially expressed between
the HMCLs with identified mutations compared to those
without identified NFKB pathway mutations. We chose
to remove two probe sets corresponding to HLA class II
genes as their expression in patient samples may also de-
rive from contaminating normal monocyte/macrophages
and B cells. The mean expression level of the remaining
four probe sets corresponding to CD74, IL2RG, and
TNFAIP3 (23) was used to represent the NFKB index.
NF-kB transcriptional activity appeared to be high in all
normal bonemarrow plasma cells, likely due to stimulation
from the surrounding microenvironment, but was variable
in MM patients and HMCL. Clearly, the presence of muta-
tions in the NF-kB pathways was associated with a higher
level of NF-kB transcription activity in the HMCLs. This
correlation was also observed in our MM patients, albeit
to a lesser degree, but the correlation is also evident in
other data sets (Figure S4). The reduced correlation be-
tween the NF-kB index and mutations seen in the patient
data setmay in part be due to the limitations inherent in the
analysis of clinical material and to other sources of NF-kB
activation originating from the bone marrow. However, in
both data sets the association of these mutations with
NF-kB transcriptional activity is not likely to result from
chance alone as a hypergeometric distrubution test, a sta-
tistical test commonly used in enrichment analysis, re-
turned p values of 0.009 and 0.04, respectively.
FISH Validation of Genetic Abnormalities
within the NF-kB Signaling Pathways
To determine the frequency of TRAF3 deletions, we blindly
screened a large cohort of MM patients by cIg-FISH, in-
cluding 60 patients initially screened by aCGH and 98 ad-
ditional patients. We identified 6 (3.8%) patients with bial-
lelic TRAF3 deletions and 19 (12.0%) patients with a single
TRAF3 allele (Table 1). There was almost complete con-
cordance between the FISH and aCGH results with the ex-
ception of two patients in whom the presence of the bial-
lelic deletion was heterogeneous by FISH and below the
detection limit of aCGH. However, in both these cases,
aCGH demonstrated a clear loss of chromosome 14,
which suggests that the biallelic deletions seen by FISH
occurred after the q-arms of chromosome 14 were lost.
To systematically screen the limited patient material for
deletions of TRAF2, cIAP1/2, and CYLD by cIg-FISH, we
selected patients for screening based on either 1N copy
number of these genes, as determined by aCGH or
a median normalized expression below 0.4. This process
identified three additional patients with cIAP1/2 deletions
and one additional patient with a CYLD biallelic deletion(C) Histogram plots of the NFKB index from normal PC, myeloma PC, and HMCL are shown and indicate the correlation between the NFKB index
and the presence of an abnormality in the NF-kB pathways. The red bar below the index corresponds to the predicted transition point between
processed versus unprocessed NFKB2. The red asterisks identify samples with questionable TRAF3 inactivation due to either a heterozygous mu-
tation call by sequencing or a biallelic deletion in less than 25% of the plasma cells.ancer Cell 12, 131–144, August 2007 ª2007 Elsevier Inc. 135
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Gene Sample Assay n Number of Gene Copies
2N/3N/4N 1N ON
TRAF3 HMCL aCGH 42a 29 (69.1) 10 (23.8) 3 (7.1)
patients FISH 158 133 (84.2) 19 (12.0) 6 (3.8)b
aCGH 62 54 (87.1) 6 (9.7)b 2 (3.2)
total 160 134 (83.7) 19 (11.9) 7 (4.4)
TRAF2 HMCL aCGH 42 35 7 0
patients FISHe 7 6 0 1
aCGH 62 60 (96.8) 1 (1.6) 1 (1.6)
cIAP1/2 HMCL aCGH 43c 36 7 3
patients FISHf 15 11 0 4
aCGH 62 60 1 1
CYLD HMCL aCGH 43d 34 (79.1) 9 (20.9) 0
patients FISHg 30 13 15 2
aCGH 62 50 (80.7) 11 (17.7) 1 (1.6)
A total of 46 HMCL were screened by aCGH; however, the 46 HMCL only represent 42 individuals because some of the lines orig-
inate from the same individual. The following HMCL were screened: ANBL-6, Delta47, EJM, FLAM-76, FR4, H1112, INA-6, JIM3,
JJN-3, JK-6L Schon, Karpas620, KHM-11, KHM-1B, KMM-1, KMS-11, KMS-12BM, KMS-12PE, KMS-18, KMS-20, KMS-26,
KMS-28BM, KMS-28PE, KMS-34, L363, LP-1, MM.1R, MM.1S, MM-M1, NCI-H929, OCI-MY1, OCI-MY5, OCI-MY7, OPM-1,
OPM-2, PE-1, PE-2, RPMI-8226, SACHI, SKMM-1, SKMM-2, U266, UTMC-2, XG-1, XG-2, XG-6, and XG-7.
a Although the aCGH defined copy number of the TRAF3 locus in KMS-11 is 1N it has been placed in the ON category as a biallelic
deletion of exon 7, an unrepresented region on the aCGH chip, was discovered during exon resequencing.
b Two patients are differentially represented in the 1N and ON categories between the FISH and aCGH result categories. In both
cases, the biallelic deletion of TRAF3was seen in a subpopulation of the light-chain-selected plasma cells while the remaining pop-
ulations show only a single copy of TRAF3. Because of this mixed population both patients are characterized as 1N by aCGH.
c The total number of HMCL is noted as 43 as KMS-28PE shows a biallelic deletion of cIAP1 and cIAP2, while the sister HMCLKMS-
28BM, derived 1 month later (T. Otsuki, Personal Communication), shows a 1N copy number.
d The total number of HMCL is noted as 43 as KMS-12BM shows a single copy of CYLDwhile the sister HMCL KMS-12PE, derived
2 months earlier (T. Otsuki, Personal Communication), shows the normal 2N copy number.
e FISH confirmed the biallelic TRAF2 deletion observed in one patient by aCGH.
fWe screened a panel of patients for cIAP1 and cIAP2 abnormalities based on their low expression of cIAP1 as detected by GEP, or
the prediction of a 1N copy number by aCGH. This panel includes 13 patients whowere not screened by aCGH. FISH confirmed the
biallelic deletion observed in one patient by aCGH.
gWe screened a panel of patients for CYLD abnormalities based on their low expression of CYLD, as detected by GEP, or the pre-
diction of a 1N copy number by aCGH. This panel includes nine patients for whom aCGH data is not available. FISH confirmed the
biallelic CYLD deletion observed in one patient by aCGH.(Table 1). No additional cases were identified with TRAF2
deletions. In summary, we identified biallelic deletions of
TRAF2, TRAF3, CYLD, or cIAP1/2 in 14/167 patients and
of TRAF3, CYLD, or cIAP1/2 in 10/67 in the Carrasco
data set. We believe that the cumulative incidence of
these abnormalities is underestimated as only TRAF3
was studied in the majority of patients due to the limited
availability of patient material.
Sequencing IdentifiesMutations of TRAF3 andCYLD
To determine the overall rate of inactivation of the identi-
fied target genes, we performed bidirectional sequencing
of the coding regions of these genes. The individual coding
exons and flanking mRNA splicing sites of TRAF3 were
sequenced in 62 patients and in the entire panel of 46
HMCLs. Through this process, we found a third HMCL,
KMS-11, with a biallelic deletion of TRAF3 originating136 Cancer Cell 12, 131–144, August 2007 ª2007 Elsevier Inc.from two independent deletions overlapping at exon 7
(data not shown). In the remaining HMCLs, we found
four independent mutations including three frameshifts
and one in-frame deletion, which are predicted to inacti-
vate TRAF3 (Figure 3, Table 2, and Table S2). All HMCL,
except the three HMCLs with biallelic deletions, ex-
pressed detectable full-length TRAF3 mRNA transcripts
and no discernable transcript length variations, suggestive
of unknown alternative splicing events, were observed.
We sequenced 49 randomly selected patient samples
for TRAF3 and identified three different mutations (one
nonsense and two missense). Subsequently, TRAF3 se-
quencing was extended to an additional 13 patients in
whom LOH of the TRAF3 locus had been characterized
by aCGH or cIg-FISH, and DNA or RNA was available
for sequencing. This process identified seven additional
abnormalities within the coding region of TRAF3, including
Cancer Cell
Mutations in the Noncanonical NF-kB Pathway in MMFigure 3. Sequencing Identifies Mutations in the Coding Region of TRAF3
A scale diagram of the TRAF3 polypeptide and the known protein domains identified by the SMART prediction tool are shown. Asterisks above the di-
agram note the position of the identified missense mutations (H70Y, R118W, Q430R, G462A, G480E, and F490C) while the nonsense, frameshift, and
deletion mutations and the associated polypeptide effects are shown below as black bars. Black bars represent normal coding regions, gray lines in-
dicate deleted regions, and thinbars represent thepositionof a frameshift and the length of translation before a stopcodon is encountered. The thin gray
bars indicated the translationof sequenceoriginatingwithin theTRAF3 locuswhile redbars indicate the translationof regionsoutsideof theTRAF3 locus.one nonsense, one frameshift, and four missense muta-
tions along with one large deletion (Table 2 and Table
S2). All of the missense mutations occur at amino acids
conserved throughout vertebrate evolution (Figure S9),
suggesting their functional relevance. Surprisingly, one
of the patients with a subpopulation of cells with a biallelic
deletion of TRAF3, MCR-0319, also had amissensemuta-
tion, which inactivates the RING domain of TRAF3
(Figure 3 and Figure S9). A domain recently shown to be
essential for the negative regulation of NIK by TRAF3 (He
et al., 2007). Altogether, TRAF3 is inactivated in 17% of
HMCL and approximately 12.3% of MM patients by eitherbiallelic deletion or by LOH associated with an inactivating
mutation.
We sequenced the coding exons of CYLD in 11 patients
with either low levels ofCYLD expression or LOHand iden-
tified a single nonsense mutation, S265X, in one patient
sample with LOH (Table 2 and Table S2). No mutations
were identified in HMCLs with LOH of CYLD (Table 2). In
the HMCL JK-6L, we identified a frameshift mutation in
NFKB2, which was investigated based on the presence
of an abnormal immunoblot band. In the only patient with
LOHof the cIAP1/2 locus,wedid not detect an abnormality
within the coding region of cIAP1 or cIAP2.Table 2. Inactivation of NF-kB Pathway Genes
Gene Sample Samples Sequenced Inactivating Mutations Inactivation
2N/3N/4N 1N ON
TRAF3 HMCL 41a 1/29 (3.4) 4/10 (40.0) 0/3 7/42 (16.7)
patients 62b 1/43 (2.3) 8/16 (50.0) 1/3 12/62 (19.4)c
CYLD HMCL 16 0/7 0/9 0/16
patients 11 0/6 1/5 1/11
An additional 15 patients were partially sequenced for TRAF3, cIAP1, cIAP2, andCYLD abnormalities at the University of Toronto. A
single patient harbored a heterozygous nonsense mutation (c.900C > T, Q183X) of TRAF3. In addition to the observed mutation,
a number of previously undocumented SNP were identified in TRAF3, CYLD, cIAP1, and cIAP2.
a OCI-MY1 was not sequenced because the entire TRAF3 locus is deleted.
b An initial panel of 49 unselected patients was screened for TRAF3 coding mutations, in which three mutations were identified.
Subsequently, a selected population of 13 patients with a single TRAF3 allele, or mixed population of 1N and ON defined by
FISH, was screened for TRAF3 mutations if template material was available for cDNA or DNA based sequencing approaches,
and this identified seven additional mutations.
c The expected frequency of TRAF3 inactivation by mutation or biallelic deletion after a 1N selection bias correction is 12.3%.
Correction Calculation = Biallelic Frequency + (1N Frequency 3 1N Mutation Frequency) + (2N/3N/4N Frequency 3 2N/3N/4N
Mutation Frequency).Cancer Cell 12, 131–144, August 2007 ª2007 Elsevier Inc. 137
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fied a promiscuous array of genetic alterations that are
predicted to result in constitutive activation of NF-kB sig-
naling. When all of the biallelic deletion events, mutations,
and gene rearrangements of TRAF2, TRAF3, cIAP1/2,
CYLD, NIK, LTBR, CD40, TACI, NFKB2, and NFKB1 are
combined, at least 28/167 (17%) MM patients and 19/46
(41.3%) HMCL have an abnormality that leads to the dys-
regulation of NF-kB signaling.
Genetic Alterations of TRAF3, BIRC2, BIRC3, CD40,
NIK, TACI, and LTBR Correlate with the Processing
of NFKB2
To determine if the genetic aberrations we identified were
associated with constitutive processing of NFKB2, we
screened the panel of HMCLs for the processing of p100
to p52 (Figure 4 and Table S3). We identified constitutive
NFKB2 processing in HMCLs with abnormalities of
TRAF3, cIAP1/2, NIK, CD40, LTBR, and TACI. As ex-
pected, the HMCLs that overexpress NIK or have TRAF3
inactivating abnormalities had constitutive NFKB2 pro-
cessing while HMCL overexpressing NFKB1, OCI-MY5,
and KMM-1 did not have detectable NFKB2 processing.
The constitutive processing of NFKB2 from p100 into
p52 correlates with both a high NFKB index and the detec-
tion of the normally cytoplasmic NFKB2 in the nucleus
(Figure 4) (Table S3). In addition, the HMCLs with inactiva-
tion of TRAF3 and rearrangements ofNIKwere associated
with detectable levels of NIK protein. Surprisingly, we also
found high levels of NIK and constitutive processing of
NFKB2 in HMCLs with cIAP1/2 biallelic deletions (Fig-
ure 4). The constitutive processing of NFKB2 seen in these
HMCLs must be linked to the absence of cIAP1 and/or
cIAP2 as the isogenic HMCL pair (KMS-28BM/PE), which
were independently derived from the bone marrow or the
pleural effusion of the same patient and share virtually
identical genomes, except for their difference in the pres-
ence (KMS-28BM) or absence (KMS-28PE) of cIAP1/2
also process NFKB2 differently. In this pair, the absence
of cIAP1/2 is associated with increased levels of NIK pro-
tein and constitutive NFKB2 processing (Figure 4). As all of
our biallelic deletions encompassed both cIAP1 and
cIAP2 and we did not identify a mutation in either gene,
we cannot determine if the loss of one or both is associ-
ated with NFKB2 processing.
Surprisingly, 2 of 3 HMCLs, L363 and EJM, with NIK ab-
normalities did not have detectable TRAF3 protein. How-
ever, the third cell line, JJN-3, which has a NIK rearrange-
ment deleting the TRAF3 interaction domain (M. Kuehl,
personal communication), had high levels of TRAF3 pro-
tein. Although it is known that TRAF3 regulates NIK protein
stability, these two observations suggest that a direct NIK-
TRAF3 interactionmay also regulate TRAF3 protein levels.
Furthermore, the high levels of TRAF3 in the cell lines lack-
ing cIAP1/2 suggest this may occur in a cIAP1/2-depen-
dent manner.
In conclusion, the majority of the genetic abnormalities
we identified in our cohort of MM patients and HMCLs
have highlighted a multifaceted mechanism that constitu-138 Cancer Cell 12, 131–144, August 2007 ª2007 Elsevier Inctively activates the noncanonical NF-kB pathway. The se-
lection of somanymutations in a single pathway highlights
its importance in myelomagenesis and identifies a poten-
tial tumor specific vulnerability.
Characterization of TRAF3 as a Tumor
Suppressor Gene
Since TRAF3 inactivation represented the most common
abnormality we identified in the noncanonical NF-kBpath-
way in MM, we investigated its potential role as a tumor
suppressor. We constructed an adenovirus capable of
high efficiency infection, which expresses wild-type
TRAF3 and used it to reintroduce TRAF3wt into the HMCLs
with TRAF3 abnormalities. Based on the well-docu-
mented role of TRAF3 as a negative regulator of NFKB2
processing, we assayed its effects on p100 processing.
In all of the HMCLs with TRAF3 abnormalities, the reintro-
duction of TRAF3wt was associated with an inhibition of
NFKB2 processing from p100 to p52 (Figure 5). In addi-
tion, overexpression of TRAF3 in the HMCL L363, which
overexpresses NIK due to an IgL translocation, leads to
a marked inhibition of NFKB2 processing.
The involvement of TRAF3 in the regulation of NIK
stability and the subsequent p100 processing is well
documented; however, a role in oncogenesis has never
been reported. We hypothesized that the inactivation of
TRAF3 would provide cells with a selective growth advan-
tage. As we predicted, the reintroduction of TRAF3wt
caused a significant growth delay in 4/5 HMCL associated
with G0/G1 cell cycle arrest and a significant increase in
apoptosis (Figure 5). The control HMCLs, OCI-MY5 and
OPM-1, that do not have constitutive processing of
NFKB2 were not affected by TRAF3 overexpression.
Inactivation of TRAF3 Is Associated with Poor
Response to Dexamethasone and a Good Response
to Proteasome Inhibitors
Proteasome inhibitors are a novel class of anticancer
agents with remarkable clinical activity in MM (Richardson
et al., 2003). Although they presumably have multiple
mechanisms of action, the principally defined mechanism
has been postulated to be the inhibition of NF-kB signal-
ing. We hypothesized that MM with constitutive activation
of the noncanonical pathway would be particularly sensi-
tive to proteasome inhibition. Unfortunately, we could not
test this hypothesis in the HMCLs, which are uniformly
sensitive to proteasome inhibitors and differ from patients
in a number of ways, most notably proliferation. Instead
we examined a GEP data set of relapsed/refractory MM
patients randomly assigned to treatment with either dexa-
methasone or the proteasome inhibitor bortezomib (Mulli-
gan et al., 2007). As we could not screen these patient
samples for mutations, we used an ROC analysis of our
patient data set to identify a median normalized expres-
sion cutoff of 0.6 as the best crossover point between sen-
sitivity and specificity and used this value as a surrogate
means of identifying patients who likely have TRAF3 ab-
normalities. In our data set, 17/25 patients with TRAF3
expression below 0.6 lack functional TRAF3. Using this.
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Mutations in the Noncanonical NF-kB Pathway in MMFigure 4. Mutations in the Noncanonical NF-kB Pathway Correlate with Processing of NFKB2 and the Presence of NFKB2 in the
Nucleus
(A) Immunoblots for the proteins of interest from the indicated HMCLs are shown. The three vertical panels are separated into a TRAF3, cIAP1, and
NIK panel plus additional HMCL when possible. For the NFKB2, TRAF3, and NIK blots, L363 and OPM-1 were included on the ends of each blot to
serve as positive and negative controls and to ensure equivalent exposure between each panel. The cIAP1 blot for L363 has been taken from another
gel as we had included KMS-18 as a negative control in all of the blot panels, and this prevented L363 from being included. In all instances the biallelic
deletion of TRAF3 or cIAP1 corresponds with the complete absence of a detectable protein product.
(B) The association between processing of NFKB2 and nuclear localization of NFKB2 was confirmed by immunofluorescence of HMCL without
NFKB2 processing (OCI-MY5) compared to thosewith constitutive NFKB2 processing (L363, NIK overexpression; OCI-MY1, TRAF3 biallelic deletion;
and U266, homozygous TRAF3 mutation).
(C) An NFKB2 immunoblot confirms the existence of NFKB2 processing in MMpatient samples and shows a correlation between the processing ratio
(left-right; positive, negative, positive, negative) and NFKB index (left-right; 1.07, 0.45, 1.26, 0.56).
(D) Immunohistochemistry of patients with a low (MCR-0459) or high (MCR-0687) NFKB index, along with a patient with a TRAF3 biallelic deletion
(MCR-0387), confirms the association between a high NFKB index or TRAF3 mutation and nuclear NFKB2. The images are representative of the
five patient samples tested fromeach category. All core biopsies but onewith sufficient plasmacells for scoring correlatedwith expectations of nuclear
NFKB2 in TRAF3 mutants or samples with high NFKB index while samples with no known mutation and a low NFKB index had cytoplasmic NFKB2.Cancer Cell 12, 131–144, August 2007 ª2007 Elsevier Inc. 139
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Mutations in the Noncanonical NF-kB Pathway in MMFigure 5. TRAF3 Reintroduction Inhibits NFKB2 Processing and Causes a Growth Arrest
The effects on HMCLs infected with an adenovirus expressing either EGFP and TRAF3WT or EGFP alone are shown.
(A) Immunoblot showing the inhibition of p100 processing 48 hr postinfection.
(B) Effects of TRAF3WT expression onMTT-defined cell growth. Infected cells were seeded 24 hr postinfection and the effects on cell growth we com-
pared to control infections at 72 hr and 96 hr postinfection. Cells were seeded at specific densities to ensure that the cells infected with the EGFP-
expressing control virus remained in the exponential phase of the growth curve at both time measurements. Error bars represent the standard
deviation.
(C) Effect of TRAF3WT expression on the cell cycle status of selected HMCL 48 hr postinfection. The scale for each plot has been normalized for each
HMCL.
(D) TRAF3WT reintroduction is associated with a significant increase in apoptosis as measured by Annexin-V staining.cutoff, 39/193 (20%) patients likely have a TRAF3 abnor-
mality, a rate similar to that observed in our cohort. In
this clinical trial data set 2/20 (10%) patients with low
levels of TRAF3 responded to dexamethasone whereas
17/19 (89%) responded to bortezomib. This was accom-
panied by a prolongation of progression-free-survival
(PFS) from 83 to 193 days (p < 0.0001). For patients with
levels of TRAF3 above 0.6, 15/50 (30%) responded to
dexamethasone and 42/104 (40%) to bortezomib, with
no difference in PFS (140 versus 145 days) (Figure S10).
These results suggest that constitutive activation of the
noncanonical NF-kB pathway by inactivation of TRAF3 is
associated with dexamethasone resistance and protea-
some inhibitor sensitivity. The resistance to dexametha-
sone was unexpected but may relate in part to the fact
that one of the mechanisms of action of glucocorticoids
targets only the canonical NF-kB pathway. It has been re-
ported that hormone-bound glucocorticoid receptor is re-
cruited to promoters by binding relA-containing dimers,140 Cancer Cell 12, 131–144, August 2007 ª2007 Elsevier Inc.thereby disrupting relA’s interaction with certain coactiva-
tors(Hoffmann andBaltimore, 2006). Onewould anticipate
that this mechanism would be of little consequence in
patients with constitutive activation of the noncanonical
NF-kB pathway. Using the top and bottom third of the
NFKB index to discriminate patients shows that patients
in the high index group have a better response rate to bor-
tezomib, although no difference in PFS. These results sug-
gest that bortezomib may be most effective in patients
with constitutive noncanonical NF-kB activation (as seen
in patients with inactivation of TRAF3).
DISCUSSION
Our integrated analysis of high-resolution aCGH and GEP
identified a plethora of genetic abnormalities resulting in
the activation of the NF-kB signaling pathways. We ob-
served overexpression and/or gain-of-function mutations
inNIK,NFKB2,NFKB1,CD40, LTBR, and TACI, which are
Cancer Cell
Mutations in the Noncanonical NF-kB Pathway in MMFigure 6. Proposed Model Indicating the Effects of the Identified Abnormalities on the Noncanonical NF-kB Pathway
The genes with inactivating abnormalities (TRAF2, TRAF3, cIAP1, cIAP2, and CYLD) are indicated by green objects while the genes with activating
abnormalities (LTBR, TACI,CD40,NIK, andNFKB2) are indicated by red objects. Based on our observations and those from other groups, we propose
the existence of a cytoplasmic NIK regulatory complex, shown in the light red hexagon, that is dependent on TRAF2, TRAF3, cIAP1, and/or cIAP2.all positive regulators of NF-kB signaling. Furthermore, we
identified inactivating abnormalities of TRAF3, cIAP1/
cIAP2, CYLD, and TRAF2, which are negative regulators
of the NF-kB pathways. Importantly, these observations
provide valuable insight into the significant contribution
of the noncanonical NF-kB pathway in the pathogenesis
of MM. In the course of this study, we have made several
compelling observations. First, TRAF3 is a tumor suppres-
sor gene that is inactivated at a frequency greater than any
other known tumor suppressor in MM. Furthermore, its re-
duced expression correlates with dexamethasone resis-
tance and bortezomib sensitivity. Second, inactivation of
cIAP1 and/or cIAP2 by biallelic deletion is associated
with an activation of the noncanonical NF-kB pathway.
Third, we found an inactivating mutation in CYLD associ-
ated with LOH, suggesting that CYLD, the causative
gene in cylindromatosis, may play a role in the develop-
ment of MM.
To date, the dysregulation of NF-kB signaling observed
in MM has largely been linked to ligand-dependent inter-actions occurring in the bone marrow. We have found
that plasma cells isolated from the bonemarrow of healthy
individuals have an elevated NF-kB transcriptional index,
suggesting that activation of NF-kB is a physiological
feature of these cells. The ligand-dependent NF-kB stimu-
lation of normal plasma cells likely serves to regulate the
growth and survival of these cells within the confines of the
bone marrow compartment. We propose that the acquisi-
tion of mutations reported here results in the accumulation
of malignant plasma cells beyond this physiological con-
trol. Our results suggest a mechanism by which MM cells
can overcome these limitations through the acquisition of
mutations that result in constitutive and ligand-indepen-
dent activation of the noncanonical NF-kB pathway.
The regulation of the noncanonical NF-kB pathway is
absolutely dependent on the presence of NIK that, al-
though constitutively transcribed, is normally undetect-
able in the absence of receptor engagement (Qing et al.,
2005), which sequesters the normally cytoplasmic local-
ized TRAF2, TRAF3, and cIAP1/cIAP2 proteins to theCancer Cell 12, 131–144, August 2007 ª2007 Elsevier Inc. 141
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et al., 2004). Based on our observations, we predict the
existence of a cytoplasmic complex regulating the co-
translational degradation of NIK, which relies on the pres-
ence of TRAF2, TRAF3, cIAP1, and/or cIAP2 (Figure 6).We
hypothesize a mechanism in which, in the absence of
stimuli, cytoplasmic TRAF3 scavenges the cytoplasm for
NIK, which is then recruited to complexes containing
TRAF2, cIAP1, and cIAP2 for degradation. Upon receptor
engagement, these regulators are sequestered to the
plasmamembrane (Kuai et al., 2003), leading to NIK stabi-
lization. We believe that anymutation affecting the binding
of these regulators to each other and to NIK would result in
NIK stabilization. In conclusion, the genetic abnormalities
we have identified are expected to contribute to the con-
stitutive processing of NFKB2 by either inhibiting the func-
tion of the NIK regulatory complex (TRAF2, TRAF3, cIAP1,
and/or cIAP2 abnormalities), bypassing or overwhelming
the NIK regulatory complex (NIK orNFKB2 abnormalities),
or by recapitulating the natural process that inactivates
the NIK regulatory complex by recruiting the various con-
stituents to the plasmamembrane (LTBR, TACI, andCD40
overexpression).
While TRAF3 is a recognized regulator of the noncanon-
ical NF-kB pathway, it has never been implicated in a ma-
lignant process. In this study, we have found that TRAF3 is
inactivated at a frequency greater than that of any other
tumor suppressor in MM. Given this frequency, we sus-
pect that other malignancies might harbor TRAF3 abnor-
malities. In fact, 21 of 83 cell lines derived from a variety
of malignancies lacked detectable TRAF3 by immuno-
histochemistry (Zapata et al., 2000).
In conclusion, we have identified a promiscuous array of
mutations that result in the constitutive activation of the
noncanonical NF-kB pathway in approximately 20% of
MM patients. The remarkable activity of bortezomib in pa-
tients with inactivation of TRAF3 suggests that one of its
most important mechanisms of action in MM is the inhibi-
tion of the noncanonical NF-kB pathway. Therefore, we
believe that the specific targeting of the direct NFKB2 reg-




Bonemarrow aspirates were collected from 167MMpatients (28 SMM
and 139 overt MM). All patients provided written informed consent ap-
proving the use of their samples under Institutional Review Board ap-
proval. The BM aspirates were treated with ACK lysis buffer to remove
red blood cells and plasma cells were isolated using immunomagnetic
sorting on aMiltenyi AutoMacs or StemCell Robocept with anti-CD138
antibodies. We enumerated 100 nucleated cells for kappa and lambda
staining to determined the purity of the CD138 sorts and found that the
mean plasma cell purity (kappa and lambda) was 95.5% (Median 96.0,
range 69%–100%) while the mean clonal purity (clinical light chain)
was 92.7% (Median 95.0, range 54–100). Isolated cells were sus-
pended in TRIzol (Invitrogen) and stored at 80C for long-term stor-
age. Nucleic acids were isolated from TRIzol following the protocol
supplied by the manufacturer. The RNA used for gene expression pro-
filing was cleaned up using the QIAGEN RNeasy kit, while the DNA142 Cancer Cell 12, 131–144, August 2007 ª2007 Elsevier Incused for aCGHwas cleaned up by phenol-chloroform extractions after
RNase and proteinase K treatments. The HMCLs were maintained as
previously described (Bergsagel et al., 1996).
Microarray Experiments
GEP of the patient samples was performed on U133A genechips fol-
lowing the manufacturer’s suggested protocol, while the 46 HMCL
samples were done on U133 Plus 2.0 (Affymetrix, Santa Clara, CA)
as previously described (Carrasco et al., 2006). Median normalized
gene expression profiles were analyzed using GeneSpring (Agilent).
High-resolution aCGH was performed on 62 patient and 46 HMCL
samples with the Human Genome 44B microarray (Agilent Technolo-
gies) following the protocol suggested by the manufacturer. Briefly,
800 ng of test (MM CD138+ cells or HMCL) and normal female refer-
ence (Promega) were directly labeled with either Cy5 or Cy3 using
the BioPrime Array CGH Genomic Labeling Module (Invitrogen) and
purified using Vivaspin 500 spin columns (Sartorius). The hybridization
reactions containing equal amounts of test and reference DNA were
hybridized to the microarray at 65C for 40 hr in a rotation oven at
20 rpm. The slides were washed and then scanned with the Agilent
G2505B DNA microarray scanner. The microarray images were ana-
lyzed using Feature Extraction software V8.1 (Agilent) and Log2 trans-
formed ratio data was analyzed with GeneSpring GX V7.3.1 and CGH
Analytics V3.4.27 (Agilent).
Sequencing
When possible individual coding exons were amplified from 10 ng of
CD138 purified plasma cell DNA in 25 ml reactions using Platinum
Taq DNA Polymerase (Invitrogen, Carlsbad CA) and M13 tagged
exon specific primes (Table S4). Alternatively, overlapping segments
of the entire open reading frame were amplified from RNA converted
to cDNA using Superscript II and oligo dT17. Sequencing reactions
were carried out using Big Dye V3.1 and capillary electrophoresis
was performed on an ABI 3730 at theMayo Clinic or TGEN sequencing
core facilities. DNA sequences were analyzed using Sequencher V4.5.
FISH
The cIg-FISH method was performed as previously described (Fon-
seca et al., 2003a). Briefly, probes specific to each region of interest
were selected using the UCSC genome browser and the specific po-
sitions were confirmed by manual mapping of the available end se-
quences to data available from HGB 36.2. The selected BAC clones
were purchased from Invitrogen and the Fosmid clones were ordered
from the BACPAC Resources Center. The specificity of each probe
was confirmed by hybridization to normal metaphase preparations to
confirm chromosome andband specificity, and gene specific PCRwas
used to confirm the presence of DNA sequence corresponding to the
specific region of interest. A list of the various FISH probes is provided
in Table S5 and amap of the different regions is provided in Figure S11.
Immunoblotting, Immunofluorescence,
and Immunohistochemistry
Total cellular extracts were prepared from freshly isolated HMCLs us-
ing 103 Cell Lysis Buffer (Cell Signaling Technologies) supplemented
with 1 mM PMSF. Protein samples were resolved on 7.5% SDS-PAGE
gels and transferred to PVDF membranes. The individual blots were
blocked with 5% nonfat milk for 1 hr and stained overnight with spe-
cific antibodies; TRAF3 H-122 (Santa Cruz), NIK (Cell Signaling),
cIAP1 (human) and cIAP2 (human) (R&D Systems), and NFKB2 (rabbit
anti-p100/p52 N-terminal polyclonal, kindly provided by Warner
Greene, UCSF). Protein bands of interest were imaged with HRP-
conjugated secondary antibodies.
The localization of NFKB2 in HMCL and selected patient core biop-
sies was determined with an NFKB2monoclonal antibody (18D10, Cell
Signaling Technology). Fresh cytospins of HMCLs were fixed in 4%
paraformaldeyde, permeabilized with 0.1% Triton X-100, and stained
with a 1:50 dilution. Confocal slices of 2 mm were collected on a Zeiss
LSM510 microscope using a 633 objective (Zeiss, Plan-Apochromat.
Cancer Cell
Mutations in the Noncanonical NF-kB Pathway in MM633/1.4 oil). Sections from available core biopsies were stained with
a 1:50 dilution.
Generation of Helper-Dependent Adenoviral Vectors
We created a helper-dependent adenoviral (HDAd) vector precursor
plasmid system capable of the simultaneous expression of EGFP
and a gene-of-interest from two different promoters near the left and
right ITRs, respectively. The original adenoviral plasmids, which have
been described previously(Shi et al., 2006), were kindly provided by
Mary Hitt (University of Alberta). First, we created the HDAd precursor
plasmid, pSC27B, by replacing the beta-galactosidase expression
cassette near the left ITR of pSC9B with a murine cytomegalovirus
(mCMV)-driven EGFP expression cassette. Second, we created the
pSC11MCPA shuttle plasmid by introducing a mCMV-MCS-SV40
poly-A cassette in between the I-SceI and I-CeuI restriction sites of
pSC11. Thus, allowing a gene-of-interest expression cassette from
pSC11MCPA to be transferred to a region near the right ITR of
pSC27B.
The full-length TRAF3 cDNA clone (Image Consortium clone
30915387) was purchased from Open Biosystems. The ORF was ex-
cised from the pCR4.0-TOPO vector with EcoRI and cloned into the
MCS of pSC11MCPA. The expression cassette was excised from
pSC11MCPA-TRAF3 with I-CeuI and I-SceI and transferred to
pSC27B to create pSC27B-TRAF3. Helper-dependent adenoviral par-
ticles were prepared by repeated cycles of amplification in 293Cre4
cells (kindly provided by Frank Graham, McMaster University) with
the adeno helper virsus AdRP2050 (Robin Parks, Ottawa Health Re-
search Institute), which contains a capsid modified by insertion of
RGD into the H1 loop of the fiber. Virus particles were purified with
a 1 hr step gradient and overnight continuous CsCl gradients as de-
scribed previously (Parks et al., 1996). Virus particles were quantified
as described previously (Ng et al., 2002). Healthy HMCLs were in-
fected with 150 viral particles per cell in 60 mm Petri plates with
2.5 3 106 cells in 5 ml of antibiotic free media. The percentage of in-
fected cells was monitored by FACS analysis of the coexpressed
GFP marker.
Functional Analysis of TRAF3wt Reintroduction
Infected HMCL were counted 24 hr postinfection and seeded at spe-
cific densities in triplicate in 96 well plates, for MTT assay, and 6 well
dishes for protein assays, apoptosis, and cell-cycle analysis. For pro-
tein assays, TRAF3wt and control infected cells were isolated 48 hr
postinfection. For cell-cycle analysis, cells were stained with propi-
dium iodide and the FACS results were modeled with ModFit LT and
chi-square value below 5. The number of apoptotic cells was deter-
mined by Annexin-V-Alexa 647 (Invitrogen) staining.
Electronic Availability of the Data
A complete list of the patient samples and various tests are provided in
Table S6. The publicly available data sets used in this paper are avail-
able in gene expression omnibus (GEO) or institutional websites as fol-
lows: Carrasco et al. GEP (GSE4452) and aCGH (http://genomic.dfci.
harvard.edu/array_cgh_db.htm). The GEP data from our patient data
set is available in the GEO database under the accession number
GSE6477. The complete data set is freely available from the Multiple
Myeloma Research Consortium Genomics Portal (http://www.broad.
mit.edu/mmgp).
Supplemental Data
The Supplemental Data include 11 supplemental figures, six supple-
mental tables, and three supplemental data sets and can be found
with this article online at http://www.cancercell.org/cgi/content/full/
12/2/131/DC1/.
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